[go: up one dir, main page]

CR20220656A - Unión de anticuerpos multiespecíficos a bcma - Google Patents

Unión de anticuerpos multiespecíficos a bcma

Info

Publication number
CR20220656A
CR20220656A CR20220656A CR20220656A CR20220656A CR 20220656 A CR20220656 A CR 20220656A CR 20220656 A CR20220656 A CR 20220656A CR 20220656 A CR20220656 A CR 20220656A CR 20220656 A CR20220656 A CR 20220656A
Authority
CR
Costa Rica
Prior art keywords
bcma
specific antibodies
antibodies binding
antibodies
binding
Prior art date
Application number
CR20220656A
Other languages
English (en)
Inventor
Nathan Trinklein
Aldred Shelley Force
Harbani Malik
Omid Vafa
Katherine Harris
Ute Schellenberger
Original Assignee
Teneobio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teneobio Inc filed Critical Teneobio Inc
Publication of CR20220656A publication Critical patent/CR20220656A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se dan a conocer anticuerpos multiespecíficos de cadena pesada humana (por ejemplo, UniAbsTM) que se unen a BCMA, junto con métodos para preparar tales anticuerpos, composiciones, incluyendo composiciones farmacéuticas, que comprenden tales anticuerpos y su uso para tratar trastornos que se caracterizan por la expresión de BCMA.
CR20220656A 2020-06-30 2021-06-30 Unión de anticuerpos multiespecíficos a bcma CR20220656A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063046477P 2020-06-30 2020-06-30
PCT/US2021/039961 WO2022006316A1 (en) 2020-06-30 2021-06-30 Multi-specific antibodies binding to bcma

Publications (1)

Publication Number Publication Date
CR20220656A true CR20220656A (es) 2023-03-01

Family

ID=77127069

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220656A CR20220656A (es) 2020-06-30 2021-06-30 Unión de anticuerpos multiespecíficos a bcma

Country Status (15)

Country Link
US (1) US20230257473A1 (es)
EP (1) EP4171750A1 (es)
JP (1) JP2023532129A (es)
KR (1) KR20230038211A (es)
CN (1) CN116472049A (es)
AU (1) AU2021300179A1 (es)
BR (1) BR112022027101A2 (es)
CA (1) CA3189297A1 (es)
CL (1) CL2022003754A1 (es)
CO (1) CO2023000808A2 (es)
CR (1) CR20220656A (es)
IL (1) IL299027A (es)
MX (1) MX2022016342A (es)
PE (1) PE20230464A1 (es)
WO (1) WO2022006316A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110945026B (zh) 2017-06-20 2024-03-19 特纳奥尼股份有限公司 仅有重链的抗bcma抗体
MX2020006494A (es) 2017-12-22 2020-11-24 Teneobio Inc Anticuerpos de cadena pesada que se unen a cd22.
SG11202111027WA (en) 2019-04-05 2021-11-29 Teneobio Inc Heavy chain antibodies binding to psma
EA202290054A1 (ru) 2019-06-14 2022-03-25 Тенеобио, Инк. Полиспецифические антитела, содержащие только тяжелые цепи, которые связываются с cd22 и cd3

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE69233254T2 (de) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanisierter Heregulin Antikörper
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
DE69731289D1 (de) 1996-03-18 2004-11-25 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
WO2001024812A1 (en) 1999-10-06 2001-04-12 N.V. Nutricia USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA
JP2004533997A (ja) 2001-02-20 2004-11-11 ザイモジェネティクス，インコーポレイティド Ｂｃｍａ及びｔａｃｉの両者を結合する抗体
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
US7608429B2 (en) 2002-10-31 2009-10-27 Genentech, Inc. Methods and compositions for increasing antibody production
CA2513113A1 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
SI2311874T1 (sl) 2004-07-22 2017-12-29 Erasmus University Medical Center Rotterdam Department of Cell Biology and Genetics Vezavne molekule
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
CA2720682A1 (en) 2008-04-25 2009-10-29 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
MX341884B (es) 2009-03-10 2016-09-07 Biogen Ma Inc Anticuerpos anti-antigeno de maduracion de celulas b (bcma).
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
JP2014500879A (ja) 2010-11-16 2014-01-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｃｍａ発現に相関性を有する疾患を治療する因子及び方法
US20130101599A1 (en) 2011-04-21 2013-04-25 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
EP3620468A1 (en) 2013-02-05 2020-03-11 EngMab Sàrl Method for the selection of antibodies against bcma
ES2688035T3 (es) 2014-08-29 2018-10-30 Gemoab Monoclonals Gmbh Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
MX2018002043A (es) 2015-08-17 2018-07-06 Janssen Pharmaceutica Nv ANTICUERPOS ANTI-BCMA, MOLí‰CULAS DE UNIí“N A ANTíGENOS BIESPECíFICAS QUE SE UNEN A BCMA Y CD3, Y USOS DE ESTOS.
JP7432363B2 (ja) 2016-06-21 2024-02-16 テネオバイオ， インコーポレイテッド Ｃｄ３結合抗体
CN109862784A (zh) 2016-08-24 2019-06-07 特尼奥生物股份有限公司 产生经修饰的仅有重链的抗体的转基因非人动物
US11505606B2 (en) 2016-09-14 2022-11-22 Teneobio, Inc. CD3 binding antibodies
WO2018224660A1 (en) 2017-06-09 2018-12-13 Armin Ehninger Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer infections and autoimmune disorders
CN110945026B (zh) * 2017-06-20 2024-03-19 特纳奥尼股份有限公司 仅有重链的抗bcma抗体
CN117866097A (zh) * 2017-06-20 2024-04-12 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
WO2019000223A1 (en) * 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
IL271597B2 (en) 2017-06-30 2024-03-01 Us Health Chimeric antigen receptors for anti-maturation B-cell antigen with human domains

Also Published As

Publication number Publication date
CO2023000808A2 (es) 2023-02-16
US20230257473A1 (en) 2023-08-17
EP4171750A1 (en) 2023-05-03
KR20230038211A (ko) 2023-03-17
AU2021300179A1 (en) 2023-02-02
BR112022027101A2 (pt) 2023-03-14
MX2022016342A (es) 2023-01-24
JP2023532129A (ja) 2023-07-26
CL2022003754A1 (es) 2023-07-07
CN116472049A (zh) 2023-07-21
PE20230464A1 (es) 2023-03-14
CA3189297A1 (en) 2022-01-06
WO2022006316A1 (en) 2022-01-06
IL299027A (en) 2023-02-01

Similar Documents

Publication Publication Date Title
ZA201908214B (en) Anti-bcma heavy chain-only antibodies
ZA201903985B (en) Anti-bcma heavy chain-only antibodies
MX2019015563A (es) Anticuerpos anti-bcma unicamente de cadena pesada.
JOP20210323A1 (ar) ارتباط أجسام مضادة ثقيلة السلسلة ومتعددة النوعية بـ cd22 وcd3
PH12021552538A1 (en) Heavy chain antibodies binding to psma
CR20220656A (es) Unión de anticuerpos multiespecíficos a bcma
SA521422031B1 (ar) مركبات 2 – فورميل – 3 – هيدروكسي فينيلوكسي ميثيل قادرة على تعديل الهيموجلوبين
MX2021000708A (es) Anticuerpos de cadena pesada que se unen al cd19.
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
PH12020550964A1 (en) Heavy chain antibodies binding to cd22
CR20220207A (es) Compuestos terapéuticos y métodos de uso
WO2018151821A8 (en) ANTI-ALPHA-SYNUCLEIN ANTIBODIES AND USES THEREOF
ZA202211667B (en) Multispecific heavy chain antibodies with modified heavy chain constant regions
MX2022001310A (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo.
MX2024001617A (es) Composiciones biofarmaceuticas.
EA202190927A1 (ru) Иммуноаблативные виды терапии
EP4252755A3 (en) Therapeutic compounds
MX2019009943A (es) Proteínas que se unen a gd2, nkg2d y cd16.
WO2022183074A3 (en) Anti-psma antibodies and car-t structures
MX2019009847A (es) Proteínas que se unen a cd123, nkg2d y cd16.
CR20230259A (es) Anticuerpos de cadena pesada que se unen al receptor de folato alfa
MX2020002802A (es) Anticuerpos de cadena pesada que se unen a ectoenzimas.
MX2023011725A (es) Anticuerpos anti-cd19 y estructuras car-t.
WO2018129451A3 (en) Anti-fgfr antibodies and methods of use
MX2022003243A (es) Conjugados anticuerpo-farmaco anti-ptcra y usos de los mismos.